Participated · Series C · Apr 2025

Attovia leverages its ATTOBODY platform, which uses spatial positioning technology to achieve biparatopic target engagement, to develop multi-specific biologics for immune-mediated diseases. Its lead candidate, ATTO-1310, is a half-life extended anti‑IL31 biologic currently in Phase 1 for chronic pruritus of unknown origin and other pruritic conditions. The company is advancing ATTO-3712, a half-life extended anti‑IL13 x IL31 bispecific, and plans to start Phase 1 studies for ATTO-3712 in the second half of 2025. Earlier-stage programs include ATTO-004, a multi-specific candidate targeting IBD, plus two discovery-stage multi-specific programs. Attovia was founded by CEO Tao Fu and is positioned to use new capital to advance its clinical and discovery-stage pipeline. The company announced board expansion alongside its financing. Attovia is developing a pipeline of biotherapeutics with an initial focus on immune-mediated diseases and uses the ATTOBODY™ biparatopic biologics platform. The platform is designed to generate binders that offer stronger efficacy and access a broader universe of druggable epitopes compared to traditional approaches. Its lead programs are ATTO-1310, a potential first-in-class, long half-life anti-IL31 ATTOBODY, and ATTO-002, a bispecific anti-IL31 x IL13 ATTOBODY targeting atopic dermatitis and other pruritic diseases. ATTO-1310 is in IND-enabling studies and is on track to enter the clinic around year-end 2024; Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025. The company raised $105M in Series B financing, bringing total funding to $165M, and plans to use proceeds to advance lead programs to initial clinical data readouts, expand its immunology and inflammation pipeline, and further develop the ATTOBODY platform. Led by CEO Tao Fu, Attovia is also developing discovery-stage programs to expand the ATTOBODY footprint to novel, difficult-to-drug targets and multi-specific combinations. Attovia Therapeutics is a California-based company developing a pipeline of biotherapeutics for immune-mediated disease and oncology built on the Attobody™ biparatopic nanobody platform. The platform produces small-format binders with low picomolar affinity, enhanced specificity, accelerated internalization and fast tissue penetration. Attovia’s lead program is an Attobody to treat immune disease; the company is progressing multiple programs and plans to initiate additional discovery projects. The company will use proceeds to achieve clinical proof-of-concept on its lead program, nominate additional development candidates across immunology and oncology, and continue to advance the Attobody technology. Attovia was launched by Alamar Biosciences and Frazier Life Sciences and will receive an exclusive worldwide license to the Attobody platform and associated IP and pipeline assets in exchange for equity and potential milestones and royalties. Tao Fu will serve as CEO; the leadership team includes CSO Petter Veiby, CTO Hangjun Zhan, and CBO Zaneta Odrowaz.

Participated · Series B · Apr 2021

Theseus Pharmaceuticals is a Boston, MA–based biotechnology company developing pan-variant tyrosine kinase inhibitors designed to anticipate and inhibit new cancer mutations. Its lead candidate, THE-630, is a next-generation pan-variant KIT inhibitor in development for the treatment of refractory GIST. The pipeline also includes a selective EGFR inhibitor intended to overcome C797S-mediated resistance to osimertinib and a third kinase-target program for an undisclosed indication. The company expects to file an IND before the end of the year. Theseus emerged from stealth concurrent with the close of a $100M Series B financing. Leadership includes co-founders William C. Shakespeare, Ph.D. (President of Research and Development) and Iain Dukes, D. Phil. (Interim CEO), and the board now includes representatives from key investors.